Byondis Will Present ADC Research in San Diego
The company will detail its novel steric masking platform and clinical progress at the upcoming World ADC conference.
Updated on Oct. 7, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize patient safety over rapid development of new cancer drugs?
Byondis B.V. is set to showcase its proprietary ByonGuard technology and the development progress of its lead candidate, BYON14156, at the World ADC conference starting October 12, 2026. The Dutch biotech firm aims to highlight its advancements in cancer therapies designed to reduce off-tumor toxicity.
Why it matters
This presentation provides insight into new antibody-drug conjugate (ADC) developments intended to overcome payload resistance and enhance patient safety in oncology. Byondis seeks to establish its integrated discovery and manufacturing platform as a viable solution for complex solid tumors.
Byondis utilizes a first-in-class antifolate payload combined with its proprietary ByonGuard steric masking technology. The company leverages over 20 years of in-house expertise to integrate discovery and manufacturing processes.
The players
Byondis B.V.
This Dutch biopharmaceutical company specializes in the development of precision medicines for cancer.
Christoph Korpus
He was appointed as the Chief Executive Officer of Byondis in April 2026.
Wim Dokter
He is a representative from Byondis scheduled to present findings on the development of BYON14156.
The details
Byondis is preparing to share data on how its platform technology targets antigens expressed across various tumor types. The firm intends to move its lead ADC candidate, BYON14156, into human clinical trials by 2027.
Timeline
October 12, 2026: Presentation on ByonGuard technology at 10:30am PDT.
October 14, 2026: Presentation on BYON14156 development at 11:00am PDT.
2027: Expected clinical trial initiation for BYON14156.
The Tech Race
The introduction of specialized steric masking technology like ByonGuard represents a shift toward more selective drug delivery systems in the crowded ADC market. Byondis is positioning its modular platform against established industry players seeking to improve the therapeutic window of toxic payloads.
For researchers and clinicians, this technology offers a potential pathway toward cancer treatments with fewer adverse side effects. The development of more precise antibody-drug conjugates may eventually lead to more tolerable chemotherapy alternatives for patients battling solid tumors.
The takeaway
Byondis is aiming to refine cancer care by masking toxic payloads until they reach their intended targets. This approach highlights an ongoing industry focus on reducing treatment-related illness for oncology patients.
What happens next
Byondis is scheduled to initiate human clinical trials for its lead ADC candidate, BYON14156, in 2027.
Further reading
Learn more about the latest innovations in the Biotech sector.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust pharmaceutical companies to prioritize patient safety over rapid development of new cancer drugs?
